E-Mail
Credit: UNSW Sydney
UNSW medical researchers have found a way to starve pancreatic cancer cells and disable the cells that block treatment from working effectively. Their findings in mice and human lab models - which have been 10 years in the making and are about to be put to the test in a human clinical trial - are published today in
Cancer Research, a journal of the American Association for Cancer Research. Pancreatic cancer has seen minimal improvement in survival for the last four decades - and without immediate action, it is predicted to be the world s second biggest cancer killer by 2025, says senior author Associate Professor Phoebe Phillips from UNSW Medicine & Health.
NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center.
The findings were published today in Clinical Cancer Research, a journal of the American Association for Cancer Research. These results led to the launch of a Phase I clinical trial to evaluate the combination of cord blood-derived NK cells (cbNK cells) with AFM13 as an experimental cell-based immunotherapy in patients with CD30+ lymphoma.
Date Time
NK cells with bispecific antibody show activity against lymphoma cells
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center.
The findings were published today in Clinical Cancer Research, a journal of the American Association for Cancer Research. These results led to the launch of a Phase I clinical trial to evaluate the combination of cord blood-derived NK cells (cbNK cells) with AFM13 as an experimental cell-based immunotherapy in patients with CD30+ lymphoma.
Molecular Templates, Inc Reports First Quarter 2021 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
News provided by
Share this article
Share this article
MARLBOROUGH, Mass., May 13, 2021 /PRNewswire/ Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended March 31, 2021 and provided a business update. This year has started out with great momentum across our pipeline, as we continue to present a steady flow of positive data that further demonstrate the value of direct therapy with INTASYL compounds, as well as their application in improving the efficacy of cell-based immunotherapy products. Results from various animal studies, including data presented at the AACR conference last month, show how INTASYL compounds directly delivered to the tumor can activate the immune re